Novo Nordisk’s amylin therapy cagrilintide shows significant weight loss in phase 3 trial
Cagrilintide represents a novel approach to obesity management
Cagrilintide represents a novel approach to obesity management
Tegoprazan, a novel patented molecule indicated for acid-related gastrointestinal diseases, is launched in India under the brand name PCAB
Products manufactured at the new Vaughan facility will support research in areas including cancer, infectious disease, mental health, and environmental safety
Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients
New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
The cGMP-4 facility will further strengthen the company's ability to serve global partners
Subscribe To Our Newsletter & Stay Updated